The FDA provided pivotal agreement on the Phase 3 design for BMD.
3 reports, 1 independent
Updated Aug 1
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA provided pivotal agreement on the Phase 3 design for BMD.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA confirmed CMC and device plans are Phase 3 ready, coinciding with strengthening of US and EU patent estates.
- Yamo Pharmaceuticals LLC plans to conduct a Phase 3 study in the US, with drug development regulated by the FDA.
- FDA provided guidance for HCW Biologics' IND application.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.
Coverage
Newest first; wire copies grouped- GlobeNewswireEntera Bio Announces Second Quarter 2025 Financial Results and Business Updates FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and c
- GlobeNewswireEntera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio